Scientific Sessions 2024  /  Navigating the Mix of Meds and Lifestyle for Obesity Medicine  /  What’s the tipping point? When to initiate pharmacotherapy and can we ever stop?
Logo

American Heart Association

  2
  0

Final ID:

What’s the tipping point? When to initiate pharmacotherapy and can we ever stop?

  • Conroy, Molly  ( University of Utah , Salt Lake City , Utah , United States )
  • Wadden, Thomas  ( UNIV OF PENNSYLVANIA , Philadelphia , Pennsylvania , United States )
  • Kushner, Robert  ( Northwestern University , Chicago , Illinois , United States )
  • Jastreboff, Ania  ( UNIV OF PENNSYLVANIA , Philadelphia , Pennsylvania , United States )
  • Almandoz, Jaime  ( UT SOUTHWESTERN MEDICAL CENTER , Dallas , Texas , United States )
  • Abushamat, Layla  ( Baylor College of Medicine , Houston , Texas , United States )
    • Author Disclosures:
    Molly Conroy: No Answer | Thomas Wadden: No Answer | Robert Kushner: DO have relevant financial relationships ; Advisor:Novo Nordisk:Active (exists now) ; Advisor:Currax:Active (exists now) ; Advisor:Altimmune:Active (exists now) ; Advisor:Structure:Active (exists now) ; Advisor:Regeneron:Active (exists now) ; Advisor:Weight Watchers:Active (exists now) ; Advisor:Eli Lilly:Active (exists now) ; Advisor:Boehringer Ingelheim:Active (exists now) | Ania Jastreboff: DO have relevant financial relationships ; Researcher:Eli Lilly:Active (exists now) ; Advisor:Regeneron:Active (exists now) ; Individual Stocks/Stock Options:Intellihealth:Active (exists now) ; Advisor:Scholar Rock:Active (exists now) ; Advisor:Structure Therapeutics:Active (exists now) ; Advisor:Zealand:Active (exists now) ; Advisor:Weight Watchers:Active (exists now) ; Advisor:Pfizer, Terns Pharmaceuticals:Active (exists now) ; Advisor:Novo Nordisk:Active (exists now) ; Advisor:Eli Lilly:Active (exists now) ; Advisor:Boehringer Ingelheim, Biohaven:Active (exists now) ; Advisor:Amgen, AstraZeneca:Active (exists now) ; Researcher:Rhythm Pharmaceuticals:Active (exists now) ; Researcher:Boehringer Ingelheim:Active (exists now) ; Researcher:Novo Nordisk:Active (exists now) | Jaime Almandoz: DO NOT have relevant financial relationships | Layla Abushamat: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Navigating the Mix of Meds and Lifestyle for Obesity Medicine

Sunday, 11/17/2024 , 03:30PM - 04:45PM

Cardiovascular Seminar

More abstracts on this topic:
Obesity Pharmacotherapy – where are we now?

Stanford Fatima, Kosiborod Mikhail

Resources for the busy clinician: engaging your patient and addressing barriers to healthy lifestyle

Dennison Himmelfarb Cheryl, Durant Raegan, Rao Goutham

More abstracts from these authors:
Association Between the Amount of Feedback Received and the Adherence to Recommended Self-monitoring and Lifestyle Goals in a Weight Loss Clinical Trial

Sereika Susan, Bizhanova Zhadyra, Beatrice Britney, Cheng Jessica, Conroy Molly, Kariuki Jacob, Parmanto Bambang, Burke Lora

Panel Discussion

Jastreboff Ania

You have to be authorized to contact abstract author. Please, Login
Not Available